Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Determine if the CYP2B6 polymorphisms associated with slower efavirenz metabolism differentially impacts loss to care in older people with HIV+ Africans

Trial Profile

Determine if the CYP2B6 polymorphisms associated with slower efavirenz metabolism differentially impacts loss to care in older people with HIV+ Africans

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Efavirenz (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 07 Sep 2018 New trial record
    • 30 Aug 2018 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top